A radical solution to anti-microbial resistance

Two different combinations of approved anti-infectives target complicated urinary tract (cUTI) and skin and soft tissue structure (ASSSI) infections in US and EU; each giving internal back-up to each other; strong competitive profile vs. current market leading products

Unique products prevent AMR by known mechanisms, so broader, longer use-life achieved

Both indications use global Ph III study supported by pre-clinical and in vitro microbiology data for US NDA by 505b2 and same EU filing routes; already proven by other combinations